Holderness Investments Co. Buys 76 Shares of Eli Lilly and Company (NYSE:LLY)

Holderness Investments Co. increased its stake in Eli Lilly and Company (NYSE:LLY) by 3.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,261 shares of the company’s stock after buying an additional 76 shares during the quarter. Holderness Investments Co.’s holdings in Eli Lilly and Company were worth $2,047,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. AMJ Financial Wealth Management bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $201,000. Aveo Capital Partners LLC increased its holdings in shares of Eli Lilly and Company by 8.2% during the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after acquiring an additional 153 shares during the last quarter. Gryphon Financial Partners LLC raised its stake in Eli Lilly and Company by 19.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after acquiring an additional 377 shares during the period. Quest Partners LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $313,000. Finally, Tidemark LLC bought a new position in Eli Lilly and Company during the fourth quarter worth $29,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Barclays upped their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the company from $725.00 to $1,025.00 in a research note on Monday, August 12th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,441 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the sale, the insider now owns 97,367,369 shares of the company’s stock, valued at $89,093,089,982.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 442,229 shares of company stock valued at $410,002,456 in the last quarter. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.7 %

Shares of LLY stock opened at $921.49 on Friday. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The stock’s fifty day moving average price is $895.06 and its two-hundred day moving average price is $838.32. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market cap of $875.79 billion, a PE ratio of 135.71, a P/E/G ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Equities analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.